ROCKVILLE, Md., Nov. 17, 2016 /PRNewswire/ -- The public listing of Siemens Healthineers announced last week makes sense from an in vitro diagnostics market perspective, according to Kalorama Information. The healthcare market research firm made its commentary in a recent blog post as news came last week that Siemens plans to divest its healthcare business, Siemens Healthineers. The move means of course that the company's in vitro diagnostic business would be part of the new entity as well as imaging and other products. Siemens did not provide an exact timing for the event and said it would depend on the stock market environment. Kalorama information estimated Siemens's IVD revenues at 5.5 billion in 2015, according to its report on the industry, The Worldwide Market for In Vitro Diagnostics, 10th Edition.
Kalorama's report is available at: http://www.kaloramainformation.com/Worldwide-Vitro-Diagnostic-10206771/. According to that report, Siemens's diagnostics business is No. 3 in IVD. Close competition with Abbott and Danaher Corp. is expected in the coming years.
"Publicly listing the company may provide resources and independent focus to help them reach into higher-revenue-growth categories and also compete with myriad companies on reaching mid-level with their Atellica solution," said Bruce Carlson, Publisher of Kalorama Information. "There are a few positives, but it stands out that the top two competitors in this space are all-healthcare companies that can find synergies in-house."
In the area of central laboratory automation Siemens is able to connect all four key laboratory disciplines—chemistry, immunoassay, hematology, and hemostasis to an automation track. The IVD business of Siemens Healthineers includes products originally from Diagnostics Products Corp. (DPC), the Bayer Diagnostics Division (without Bayer Diabetes Care) and Dade Behring. The diagnostics division includes products for: clinical chemistry, drug testing, hematology, coagulation, immunoassay, infectious diseases, microbiology, molecular diagnostics, plasma proteins, point of care testing, blood gases/electrolytes, and urinalysis. In addition Siemens operates a clinical laboratory and offers laboratory informatics and automation.
Siemens has made several moves aimed at growth in recent years. In July 2014, Beckman Coulter agreed to acquire Siemens Healthcare Diagnostics' MicroScan microbiology product line that includes the MicroScan Instruments and MicroScan panels/consumables, along with data management solutions. Siemens stated the divestiture would allow the company to concentrate on its molecular business. In April 2016, Siemens further strengthened its molecular business. Siemens Healthcare and Thermo Fisher Scientific announced collaboration that includes the integration of Thermo Fisher Scientific's real-time PCR system into Siemens' VERSANT kPCR Molecular Solution.
Kalorama Information's The Worldwide Market for In Vitro Diagnostics has detailed market sizes and forecasts for scores of test markets and has market share and recent revenues for top 20 IVD companies, dozens of specialist/secondary players and hundreds of competitive growth companies. The report is available on Kalorama Information's website.
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.
We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog on our company website.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/siemens-healthineers-divestiture-a-logical-step-says-ivd-research-company-300364669.html
SOURCE Kalorama Information